Form 4 for TXG 10x Genomics, Inc.
Accepted 2022-12-16 00:00:00 ET · period of report 2022-12-14 · accession 0001567619-22-021727 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-16 | 2022-12-14 | TXG | Hindson Benjamin J. | See Remarks, Dir | M - OptEx | $5.04 | +34.3K | 252.0K | +16% | +$172.7K |
| D | 2022-12-16 | 2022-12-14 | TXG | Hindson Benjamin J. | See Remarks, Dir | M - OptEx | $0.00 | -34.3K | 13.0K | -73% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-12-14 | M | A | 34,266 | $5.04 | 251,979 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2022-12-14 | M | D | 34,266 | $0.00 | 12,972 | D | $5.04 · — to 2028-11-02 | 34,266 Class A Common Stock | (F1) All of the shares subject to the option are fully vested and exercisable as of the date hereof. |